AVITA Medical Reports First Quarter 2026 Financial Results
AVITA Medical reported Q1 2026 revenue of $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by Cohealyx contributions and normalized RECELL utilization. Operating expenses fell 11% year-over-year to $24.5 million due to cost optimization initiatives, resulting in a net loss of $10.6 million ($0.35 per share), an improvement from the $13.9 million loss in Q1 2025. The company appointed Cary Vance as CEO and Jan Stern Reed as independent Board Chair, while reaffirming full-year 2026 revenue guidance of $80M-$85M.
Key figures
- Revenue
- 19251000
- Guidance
- FY26 revenue $80M-$85M (12-19% YoY growth)
- Revenue Yoy
- 4%
- Net loss
- 10611000
- Gross margin
- 81.7%
- Gross profit
- 15728000
- Net cash use
- 9900000
- Operating loss
- 8803000
- Operating expenses
- 24531000
- Cash and securities
- 14300000
- Barda agreement value
- 25500000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.